The Journal of managed care and specialty pharmacy 2023 Dec;29(12):1321-1330.doi: 10.18553/jmcp.2023.29.12.1321. Marie-Ange Paget, Antje Tockhorn-Heidenreich, Mark Belger, Florence Chartier, Michel Lantéri-Minet Abstract Background: Health care decision makers are often concerned about the external validity of randomized controlled trials (RCTs), as their results may not
Study of severe migraine in general medicine
Revue Neurologique (Paris) 2023 Aug 8:S0035-3787(23)00979-7.doi: 10.1016/j.neurol.2023.01.730. Online ahead of print. J Henri, S Redon, A Donnet Abstract Objective: To evaluate the criteria of severe migraine in a general population consulting a general practitioner (GP) and to evaluate assessment of migraine
Cyclic vomiting syndrome, a common language? A 20-year bibliometric study
Acta neurologica Belgica 2023 Mar 29. doi: 10.1007/s13760-023-02223-z. Online ahead of print. Sylvain Redon, Anne Donnet Abstract Background: Cyclic vomiting syndrome (CVS) is recognized as an episodic syndrome associated with migraine in the last version of the International Classification of Headache
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
The Lancet Neurology 2022 Jul;21(7):597-607 doi: 10.1016/S1474-4422(22)00185-5. Messoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling Abstract Background: The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
The journal of headache and pain 2022 May 3;23(1):53 doi: 10.1186/s10194-022-01424-w. Alexandre O Gérard, Diane Merino, Elise K Van Obberghen, Fanny Rocher, Alexandre Destere, Michel Lantéri-Minet, Milou-Daniel Drici Abstract Background: Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide
Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies
Current Medical Research and Opinion 2022 May 13;1-18 doi: 10.1080/03007995.2022.2076475. Online ahead of print. Serge Perrot, Alain Eschalier, Jules Desmeules, Michel Lanteri-Minet, Nadine Attal Abstract Background: Paracetamol is the commonest analgesic worldwide in primary care. Despite evidence-based recommendations for management of acute and chronic
Regulation of two-pore-domain potassium TREK channels and their involvement in pain perception and migraine
Neuroscience letters 2022 Mar 16;773:136494 doi: 10.1016/j.neulet.2022.136494. Epub 2022 Jan 31. Pablo Ávalos Prado, Anne-Amandine Chassot, Arnaud Landra-Willm, Guillaume Sandoz Abstract The ability to sense pain signals is closely linked to the activity of ion channels expressed in nociceptors, the first neurons that
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study
Journal of Neurology, Neurosurgery and Psychiatry 2022 March 09;jnnp-2021-327480 Michel Dominique Ferrari, Uwe Reuter, Peter J Goadsby , Gabriel Paiva da Silva Lima, Subhayan Monda, Shihua Wen, Nadia Tenenbaum, Shaloo Pandhi, Michel Lanteri-Minet, Tracy Stites Abstract Objective: To evaluate individual
Hemiplegic Migraine Associated With PRRT2 Variations: A Clinical and Genetic Study
Neurology 2022 Jan 4;98(1):e51-e61. doi: 10.1212/WNL.0000000000012947. Epub 2021 Oct 14. Florence Riant, Caroline Roos, Agathe Roubertie, Cécile Barbance, Jessica Hadjadj, Stéphane Auvin, Guillaume Baille, Marion Beltramone, Cécile Boulanger, Alice Cahn, Florina Cata, Emmanuel Cheuret, Jean-Christophe Cuvellier, Antoine Defo, Genevieve Demarquay, Anne Donnet, Nicolas Gaillard, Evelyne Massardier, Nathalie Guy, Sylvie Lamoureux , Laurence Le Moigno, Christian Lucas, Diana Ratiu, Sylvain Redon, Caroline Rey , Christel Thauvin
Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My- LIFE European Delphi survey
European Journal of Pain 2021 Nov;25(10):2177-2189 doi: 10.1002/ejp.1831. Epub 2021 Jul 13. Patricia Pozo-Rosich, Raquel Gil-Gouveia, Anne Donnet, Anne-Christine Poole, Astrid Gendolla, Shazia Afridi, Rainel Sanchez-De la Rosa, Gisela M Terwindt, Cristina Tassorelli Abstract Background: Clinical guidelines agree that preventive treatment should be considered in patients with uncontrolled